Catalog No.
Product Name
Application
Product Information
Citations
-
COX-2/HDAC Inhibitor
Andrographidine E is an inhibitor of cyclooxygenase-2 (COX-2) and histone deacetylases (HDAC), with an IC50 of 19 μM for COX-2 and a strong affinity for HDAC1 and HDAC3. This compound selectively binds to macrophages, suggesting its potential as an immunotargeting agent. Andrographidine E is valuable for research applications focused on inflammation and immune modulation. -
BChE/HDAC6 Inhibitor
BChE/HDAC6-IN-2 is a potent dual inhibitor targeting both butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6), demonstrating IC50 values of 1.8 nM and 71.0 nM, respectively. This compound exhibits significant neuroprotective properties and scavenges reactive oxygen species (ROS), alongside effectively chelating metal ions such as Fe2+ and Cu2+. Furthermore, BChE/HDAC6-IN-2 inhibits tau phosphorylation and presents moderate immunomodulatory effects, making it a valuable reagent for research into neurodegenerative diseases and related pathways. -
AChE/HDAC Inhibitor
AChE/HDAC-IN-1 is a potent dual inhibitor of acetylcholinesterase (AChE) and histone deacetylases (HDAC) with IC50 values of 0.12 nM and 0.23 nM, respectively. This compound also demonstrates antioxidant activity and metal chelating properties, making it a valuable tool in understanding neurodegenerative processes. AChE/HDAC-IN-1 is suitable for research applications related to Alzheimer's disease and other conditions associated with cholinergic dysfunction and epigenetic modifications. -
HDAC6 Inhibitor
HDAC6-IN-5 is a potent inhibitor of histone deacetylase 6 (HDAC6), demonstrating an IC50 of 0.025 μM. This compound effectively inhibits the self-aggregation of amyloid-beta 1-42 and acetylcholinesterase (AChE), with IC50 values of 3.0 μM and 0.72 μM, respectively. HDAC6-IN-5 has been shown to promote neurite outgrowth while exhibiting minimal neurotoxicity, making it a valuable tool for research in neurodegenerative disease and neuronal regeneration studies. -
HDAC6 Inhibitor
HDAC6-IN-6 is a potent inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 0.025 μM. This compound is capable of crossing the blood-brain barrier and demonstrates strong inhibitory activity against amyloid-beta peptide (Aβ1-42) self-aggregation and acetylcholinesterase (AChE) with IC50 values of 3.0 μM and 0.72 μM, respectively. Additionally, HDAC6-IN-6 enhances neurite outgrowth while maintaining a favorable safety profile, making it a valuable tool for research in neurodegenerative diseases and related fields. -
BChE/HDAC6 Inhibitor
BChE/HDAC6-IN-1 is a selective dual inhibitor targeting both butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6), with IC50 values of 4 nM and 8.9 nM, respectively. This compound demonstrates significant potential in ameliorating cognitive impairment in an Aβ1–42-induced mouse model, making it a valuable tool in Alzheimer's disease research. Its ability to modulate both cholinergic and epigenetic pathways positions BChE/HDAC6-IN-1 as a promising candidate for studies focused on neurodegenerative disorders. -
Histone Methyltransferase
Lobelane hydrochloride selectively inhibits the vesicular monoamine transporter-2 (VMAT2). This compound demonstrates an affinity for VMAT2 with a K(i) value of 630 nM, while exhibiting low interaction with nicotinic acetylcholine receptors (nAChR). The unique mechanism of action of lobelane hydrochloride makes it a valuable tool for studying neurotransmitter dynamics and offers potential in the development of therapeutic agents aimed at addressing methamphetamine abuse. Its structural analogs may further expand its applications in neuropharmacological research. -
Geranylated Flavanone
Diplacone is a geranylated flavanone derived from the unripe fruits of Paulownia tomentosa. It exhibits significant anti-inflammatory, antiradical, cytoprotective, antibacterial, and anticancer properties. Diplacone induces ferroptosis-mediated cell death through mechanisms involving increased mitochondrial Ca2+ influx, reactive oxygen species (ROS) production, and mitochondrial permeability transition. Additionally, it effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activity, making it valuable for research into chronic inflammatory diseases, cancers, and neurological disorders such as Alzheimer's disease. -
P2X7 Antagonist
Bullatine A is a potent P2X7 antagonist with significant anti-inflammatory and anti-nociceptive properties. It effectively inhibits ATP-induced BV-2 cell apoptosis and modulates inflammatory responses mediated by P2X receptors. Bullatine A has demonstrated the ability to reduce glioma cell growth by targeting SIRT6, alleviate pain hypersensitivity in rodent models, and mitigate systemic inflammation via the ROS/JNK/NF-κB pathway. Additionally, it has shown potential in improving behavioral outcomes in models of chronic social defeat stress. This compound is valuable for research in inflammation, glioblastoma, and depression. -
Anti-inflammatory agent, AChE Inhibitor, P450 Inhibitor, Neuroprotective agents
Acetylshikonin is a potent anti-inflammatory agent that also functions as an inhibitor of acetylcholinesterase (AChE) and non-selective cytochrome P450 enzymes. With an IC50 of 34.6 μM for AChE, Acetylshikonin exhibits neuroprotective properties and can induce apoptosis and autophagy in cancer cells. Its ability to regulate blood glucose and liver fat metabolism makes it valuable in research related to diabetes, diabetic nephropathy, obesity, and nonalcoholic fatty liver disease. -
COX Inhibitor
[8]-Shogaol is a potent inhibitor of cyclooxygenase (COX), specifically targeting COX-2 with an IC50 of 17.5 μM. This compound exhibits significant antiplatelet properties (IC50=5 μM) and demonstrates anti-cancer and anti-inflammatory activities. Additionally, [8]-Shogaol modulates key signaling pathways by inhibiting TAK1, IKK, and Akt, thereby influencing MAPK signaling and alleviating synovitis. Its unique pharmacological profile makes it a valuable reagent for research in cancer, inflammation, and cardiovascular diseases. -
Cholinesterase (ChE) Inhibitor
Scopoletin is a cholinesterase inhibitor that primarily targets acetylcholinesterase (AChE). It possesses notable biological activity in preventing the breakdown of acetylcholine, thereby enhancing cholinergic transmission. Scopoletin is commonly used in research focused on neurodegenerative diseases, cognitive disorders, and potential therapeutic interventions involving cholinergic systems. -
COX Inhibitor
Diclofenac potassium is a potent nonselective inhibitor of cyclooxygenase (COX) enzymes, demonstrating IC50 values of 4 nM for human COX-1 and 1.3 nM for human COX-2 in CHO cells, along with 5.1 μM and 0.84 μM for ovine COX-1 and COX-2, respectively. This reagent exhibits significant anti-inflammatory properties and is particularly effective in inducing apoptosis in neural stem cells through the activation of the caspase cascade. It is widely used in research studies focusing on inflammatory pathways and neural stem cell biology. -
Stable Isotope
Penconazole-d7 is a deuterium-labeled derivative of Penconazole, a triazole fungicide primarily utilized for the management of powdery mildew in crops such as apples, grapes, and vegetables. This compound exerts its biological activity by inhibiting sterol biosynthesis in fungi, thereby disrupting cell membrane integrity. Additionally, Penconazole has been shown to decrease acetylcholinesterase (AChE) activity in the cerebrum and cerebellum of rat models, making it relevant for neurobiological research applications. -
Fungicide
Iprobenfos is an organophosphorus fungicide primarily targeting the rice blast fungus. Its mechanism involves the phosphorylation of the -OH group on serine residues located within the active site of cholinesterases, leading to the inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities. This compound is significant in agricultural research for its role in managing fungal diseases in crops and understanding the interaction of organophosphorus compounds with cholinergic systems. -
Anti-inflammation/Infection Agent
β-Amyrone is a triterpene compound recognized for its anti-inflammatory properties, primarily through the inhibition of cyclooxygenase-2 (COX-2) expression. It demonstrates significant antifungal activity and exhibits antiviral effects against the Chikungunya virus. Additionally, β-Amyrone inhibits α-glucosidase and acetylcholinesterase (AChE) activities, making it a valuable compound for research in inflammation, infectious diseases, and obesity-related studies. -
Fungicide
Penconazole is a triazole fungicide that targets sterol biosynthesis in fungi, effectively inhibiting their growth. It is primarily utilized in the agricultural sector for the control of powdery mildew on crops such as apples, grapes, and various vegetables. Additionally, studies indicate that Penconazole may reduce acetylcholinesterase (AChE) activity in the cerebrum and cerebellum of rats, suggesting potential implications for neurobiological research. -
EGFR/HER2/CDK9/COX-2 Inhibitor
CDK9-IN-41 is a potent inhibitor of CDK9, EGFR, HER2, and COX-2, exhibiting IC50 values of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM respectively. This compound demonstrates significant antitumor activity across various cancer cell lines, including leukemia, colon, melanoma, ovarian, and breast cancer. It serves as a valuable tool for exploring the role of these kinases in cancer biology and therapeutic applications. -
CaMK II Inhibitor
Lavendustin C is a selective inhibitor of calcium/calmodulin-dependent kinase II (CaMK II), exhibiting an IC50 of 0.2 µM. In addition to its primary mechanism, Lavendustin C also targets epidermal growth factor receptor (EGFR)-associated tyrosine kinase with an IC50 of 0.012 µM and pp60c-src(+) kinase at an IC50 of 0.5 µM. This compound is valuable in research applications focused on signaling pathways involving CaMK II and its associated kinases, aiding in the study of various cellular processes and potential therapeutic interventions. -
Fluorescent Substrate APP+
IDT307 is a fluorescent substrate targeting the dopamine transporter (DAT). As an analog of the organic cation MPP+, it exhibits specific fluorescent properties that enable the visualization of DAT activity in various biological contexts. This compound is valuable for research applications focusing on dopamine signaling, drug interactions, and neurodegenerative disease models. -
PDE Inhibitor
Flavoxate hydrochloride is a competitive inhibitor of phosphodiesterase (PDE), providing significant antispasmodic effects through its action as a muscarinic acetylcholine receptor (mAChR) antagonist. In addition to its PDE inhibition, it exhibits moderate calcium antagonistic properties and local anesthetic effects. Flavoxate hydrochloride is utilized in research focused on overactive bladder (OAB) and related lower urinary tract infections, contributing to a better understanding of these conditions and potential therapeutic approaches. -
COX-1/cAMP Phosphodiesterase Inhibitor
Triflusal is a dual inhibitor of Cyclooxygenase-1 (COX-1) and cAMP phosphodiesterase, which penetrates the blood-brain barrier. It effectively inhibits platelet aggregation, nuclear factor kappa B (NF-κB) activation, inducible nitric oxide synthase (iNOS) activity, and prostaglandin synthesis in ischemic tissues. Additionally, Triflusal enhances neutrophil nitric oxide production, endothelial nitric oxide synthase (eNOS) expression, and constitutive nitric oxide synthase (cNOS) activity. This compound is valuable for investigating thromboembolic and ischemic diseases of the cardiovascular and cerebrovascular systems, as well as Alzheimer's disease pathology. -
5-HT Receptor Antagonist
T 82 is a potent 5-HT3 receptor antagonist that also functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant biological activity relevant for modulating neurotransmitter signaling in the central nervous system. T 82 is primarily utilized in research related to neurodegenerative diseases, including Alzheimer's Disease, making it a valuable tool in understanding the pathophysiology and treatment approaches for related conditions. -
α7 nAChR Agonist/5-HT3 antagonist
(S)-PNU-282987 hydrochloride is a potent agonist of the α7 nicotinic acetylcholine receptor (nAChR), exhibiting an EC50 of 154 nM. In addition, it acts as a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. This compound is valuable for research applications exploring the central and peripheral nervous systems, facilitating the study of neurotransmission and signaling pathways involving cholinergic and serotonergic systems. -
Dopamine Transporter Inhibitor
LR1143 is a potent inhibitor of the dopamine transporter (DAT), exhibiting an IC50 value of 3.4 nM in rat models. This compound also inhibits 5-HT uptake, with an IC50 of 112 nM, indicating its broader influence on serotonin reuptake sites. LR1143 demonstrates a strong binding affinity for DAT, as evidenced by its interaction with the dopamine reuptake inhibitor GBR 12935, and offers utility in research focused on cocaine abuse and other neuropharmacological studies. -
nAChR Agonist
Facinicline (RG3487) is an orally active partial agonist of the nicotinic α7 receptor, exhibiting a Ki of 6 nM for human nAChR. This compound has been shown to enhance cognitive function and sensorimotor gating in rodent models, providing a valuable tool for research into cognitive disorders. Additionally, Facinicline hydrochloride demonstrates high affinity as an antagonist at 5-HT3 receptors with a Ki value of 1.2 nM, further broadening its potential applications in neuroscience research. -
5-HT Agonist
Serotonin maleate acts as a selective agonist for 5-HT receptors in the central nervous system, influencing various physiological processes, including mood regulation and cognitive function. Additionally, it serves as a catechol O-methyltransferase (COMT) inhibitor with a Ki value of 44 μM, making it valuable for research involving neurotransmitter dynamics and the modulation of serotonergic pathways. Its multiple biological activities position it as a critical reagent for studies in neuroscience and pharmacology. -
DAT/NET/SERT Inhibitor
DOV-102,677 is a potent triple reuptake inhibitor targeting the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). It exhibits inhibitory potency with IC50 values of 129 nM for DAT, 103 nM for NET, and 133 nM for SERT. This compound has shown significant antidepressant-like effects and modulates sensory-motor gating in preclinical mouse models. DOV-102,677 is suitable for investigations into the mechanisms of depression and related neuropharmacological research. -
AChE/SERT Inhibitor
BGC-201259 is a potent and orally active inhibitor of acetylcholinesterase (AChE) and serotonin transporter (SERT), with IC50 values of 101 nM and 42 nM, respectively. Additionally, it inhibits the 5-HT receptor with an IC50 of 90 nM. BGC-201259 exhibits varying activity against several targets, including the norepinephrine transporter (IC50 = 7.7 μM), L-type calcium channel (IC50 = 3.6 μM), σ receptor (IC50 = 2 μM), and sodium channel (IC50 = 5.1 μM). This compound shows promise in research related to Alzheimer's disease by potentially enhancing cognitive and emotional functions through its dual-targeting mechanism. -
AChE Inhibitor
Flucopride is an AChE inhibitor with an IC50 of 24 nM, demonstrating significant potency in acetylcholinesterase modulation. Additionally, it acts as a partial agonist at the 5-HT4 receptor with a binding affinity (Ki) of 9.6 nM. Flucopride facilitates non-amyloidogenic processing of amyloid precursor protein (APP) in COS-7 cells expressing the human 5-HT4 receptor, with an EC50 of 23.0 nM. Its properties suggest effective gastrointestinal tract penetration and the capability to cross the blood-brain barrier, as indicated by PAMPA assay results, making it relevant for neuropharmacology research. -
α7-nAChR Agonist
GTS-21 is a selective agonist of the alpha7 nicotinic acetylcholine receptor (α7-nAChR), known for its anti-inflammatory and cognitive-enhancing properties. Additionally, GTS-21 exhibits antagonistic activity at the α4β2 receptor (Ki=20 nM) and the 5-HT3A receptor (IC50=3.1 μM). This compound is utilized in research related to age-associated memory impairment (AAMI) and Alzheimer's disease, making it a valuable tool for investigating cognitive dysfunction and neuroinflammatory processes. -
NMDA Antagonist
Ensaculin free base is a potent NMDA antagonist that exhibits high affinities for serotonergic 5-HT1A and 5-HT7 receptors, as well as adrenergic α1 and dopaminergic D2 and D3 receptors. This compound has demonstrated memory-enhancing properties and shows potential as an antidementia agent, influencing multiple neurotransmitter systems. Its diverse receptor activity makes it a valuable tool for researching cognitive function and neurodegenerative disorders. -
MDMA Derivative
EDMA hydrochloride is a derivative of MDMA that acts primarily as a substrate for various neurotransmitter transporters, including the serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). This compound exhibits significant biological activity, demonstrating 5-HT releasing capability at SERT with an EC50 of 117 nM, as well as MPP+ releasing activity at DAT (EC50 = 597 nM) and NET (EC50 = 325 nM). EDMA hydrochloride is utilized in research applications related to neurotransmitter dynamics and psychoactive substance studies. -
Stable Isotope
Serotonin-13C,D4 (5-Hydroxytryptamine-13C,D4) is a stable isotope-labeled form of serotonin, featuring carbon-13 and deuterium isotopes. As a monoamine neurotransmitter, it serves as an endogenous agonist of 5-HT receptors in the central nervous system (CNS). Additionally, Serotonin-13C,D4 acts as a catechol O-methyltransferase (COMT) inhibitor, demonstrating a Ki value of 44 μM. This reagent is valuable for research in neurobiology, pharmacology, and metabolic studies involving serotonin signaling and metabolism. -
COX Inhibitor
Pentagamavunon-1 (PGV-1) is a COX-2 inhibitor that modulates multiple molecular pathways to induce apoptosis. This Curcumin analog exhibits notable oral bioactivity and suppresses key angiogenic factors, including vascular endothelial growth factor (VEGF). Additionally, PGV-1 inhibits NF-κB activation, highlighting its potential in cancer research and therapeutic applications targeting inflammation and tumor progression. -
Stable Isotope
Dimethoate-d6 is a deuterium-labeled analogue of Dimethoate, an organophosphate insecticide and acaricide. It functions primarily as an acetylcholinesterase inhibitor, leading to enhanced neurotransmitter activity. This compound demonstrates significant biological activities, including the induction of reactive oxygen species (ROS), DNA damage, and cell apoptosis in vivo. Additionally, Dimethoate-d6 has been shown to affect immune system responses in murine models, making it a valuable tool for research in toxicology and environmental sciences. -
γ-Secretase Inhibitor I
Z-LLNle-CHO is a γ-secretase inhibitor that effectively disrupts the Akt-mediated pro-survival signaling pathway, leading to caspase activation and ROS-dependent apoptosis. This compound is instrumental in cancer research, particularly in the studies of breast cancer and leukemia, where inhibiting γ-secretase activity may provide insights into therapeutic strategies. -
P2X2/3 Receptor Antagonist
Minodronic acid hydrate is a third-generation bisphosphonate that acts as an antagonist of the purinergic P2X2/3 receptors. It demonstrates the ability to inhibit the proliferation of cancer cells, induce apoptosis, and restrict metastasis in various cancer types. This compound is particularly relevant in pain research, providing insights into its role in managing nociception associated with P2X2/3 receptor activity. -
Apoptosis Inhibitior
(S)-Oxiracetam is an apoptosis inhibitor that targets the PI3K/Akt/GSK3β signaling pathway via α7 nAChR activation. It has demonstrated efficacy in reducing brain infarct size and alleviating neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. This compound effectively prevents neuronal apoptosis, making it a valuable research tool for studies focused on ischemic stroke and neuroprotection. -
Stable Isotope
Galanthamine-d6 is a deuterium-labeled derivative of Galanthamine, a potent inhibitor of acetylcholinesterase (AChE) with an IC50 value of 500 nM. This stable isotope compound is valuable in pharmacokinetic studies and metabolic research, particularly in exploring the mechanisms of cholinergic modulation. Its isotopic labeling helps in the precise tracking of metabolite pathways in biological assays. -
Phenolic Compound
Cardanol monoene is a phenolic compound derived from cashew nut shell liquid, primarily targeting cellular mechanisms involved in cancer progression. It exhibits significant anti-cancer activities, including the inhibition of cell proliferation and migration, S phase arrest, and induction of apoptosis via reactive oxygen species (ROS) production and mitochondrial depolarization. Cardanol monoene modulates key signaling pathways by downregulating MMP-2 and MMP-9 expressions and regulating the expression of CDK2, p53, and Bax, among others. Additionally, it demonstrates weak DPPH radical scavenging and acetylcholinesterase inhibition activities, making it suitable for research in cancer, infection, and inflammation. -
Stable Isotope
Tolcapone-d4 is a deuterated derivative of the selective catechol-O-methyltransferase (COMT) inhibitor, Tolcapone. This compound exhibits an IC50 of 773 nM, demonstrating its potency in inhibiting COMT activity. Tolcapone-d4 is utilized in research related to neurodegenerative disorders and cancer, as it influences α-synuclein and amyloid-beta oligomerization and fibrillogenesis. Additionally, it has been shown to induce oxidative stress, promote apoptosis in cancer cells, and increase reactive oxygen species (ROS) production, making it valuable for studies in both cancer and neurological disease contexts. -
AChE Inhibitor
Kokusaginine is a furoquinoline alkaloid that acts as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 28.2 μM. This compound has demonstrated anti-proliferative and apoptotic effects in MCF-7/ADR cancer cell lines, making it a valuable reagent for research in neurobiology and cancer biology. Its ability to modulate cholinergic signaling and induce cell death highlights its potential for further investigation in therapeutic applications. -
CDK2/9 Inhibitor
ZLMT-12 is a potent CDK2/9 inhibitor, demonstrating IC50 values of 0.002 μM and 0.011 μM against CDK9 and CDK2, respectively. This compound is derived from tacrine and exhibits weak inhibition of acetylcholinesterase (IC50 = 19.023 μM) and butyrylcholinesterase (IC50 = 2.768 μM). ZLMT-12 is characterized by low toxicity and notable antiproliferative activity, effectively inducing apoptosis and facilitating cell cycle arrest in the S and G2/M phases. This compound serves as a valuable tool for research in cell cycle regulation and therapeutic development in cancer biology. -
COX Inhibitor
Ketorolac hemicalcium is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective cyclooxygenase (COX) inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in research related to allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain, as well as for its potential applications in cancer research due to its role as a DDX3 inhibitor. -
COX Inhibitor
Metamizole magnesium is an orally active cyclooxygenase (COX) inhibitor known for its key roles in reducing inflammation and pain. It exhibits significant anti-inflammatory and antioxidant activities, along with the ability to inhibit cell proliferation and promote apoptosis. Due to its antipyretic and analgesic properties, Metamizole magnesium is commonly utilized in various research applications aimed at investigating pain mechanisms and inflammatory responses. -
Topo I/COX-2 Inhibitor
Topo I/COX-2-IN-1 is an inhibitor of both Topoisomerase I and Cyclooxygenase-2 (COX-2). It demonstrates significant biological activity, with IC50 values of 0.24 μM for COX-2 and 4.42 μM for Topo I. This compound effectively induces apoptosis and inhibits the migration of cancer cells, showcasing potential applications in cancer research and therapy. -
Topo I/COX-2 Inhibitor
Topo I/COX-2-IN-2 is a potent dual-target inhibitor of Topoisomerase I (Topo I) and Cyclooxygenase-2 (COX-2), exhibiting inhibitory concentrations (IC50) of 0.90 μM and 2.31 μM, respectively. This compound induces apoptosis in cancer cells via the mitochondrial pathway, making it a valuable agent for research in cancer therapeutics and cell death mechanisms. Its dual activity supports investigations into the interplay between topoisomerase inhibition and inflammatory pathways in cancer progression. -
Drug Metabolite
3-O-Methyltolcapone is a drug metabolite derived from Tolcapone, a selective and potent inhibitor of catechol-O-methyltransferase (COMT) with an IC50 of 773 nM. This compound is known to block α-synuclein and Aβ42 oligomerization and fibrillogenesis, while also inducing oxidative stress, apoptosis in cancer cells, and reactive oxygen species (ROS) production. Research applications include studies related to cancer and neurological disorders, particularly in the context of Parkinson’s disease and neuroblastoma. -
Celecoxib Analog
OSU-03013 is a Celecoxib analog that targets multiple pathways involved in cancer progression. It promotes apoptosis while enhancing E-cadherin expression and reduces β-catenin, c-myc, Wnt1, and N-cadherin levels. By inhibiting cell migration and invasion, OSU-03013 effectively regulates Wnt and mTOR signaling, leading to decreased proliferation of colon cancer cells. This compound is suitable for research focused on colon cancer and its underlying mechanisms.
